[시장보고서]수의용 줄기세포 치료 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

수의용 줄기세포 치료 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Veterinary Stem Cell Therapy Market Size, Share & Trends Analysis Report By Product, By Animal Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1908144

리서치사 : Grand View Research

발행일 : 2025년 12월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,615,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,062,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,958,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

수의용 줄기세포 치료 시장 요약

세계의 수의용 줄기세포 치료 시장 규모는 2024년에 1억 5,407만 달러로 추정되며, 2033년까지 3억 1,103만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 8.62%의 CAGR을 기록할 것으로 예상됩니다. 본 산업은 반려동물의 만성 및 퇴행성 질환 발생률 증가, 줄기세포 치료 기술의 지속적인 발전, 반려동물의 인간화 경향의 증가, 그리고 반려동물 보호자들의 첨단 수의학에 대한 투자 의욕 증가에 힘입어 괄목할만한 성장을 거듭하고 있습니다.

또한, 수의학 분야의 첨단 질병 변형 치료에 대한 수요 증가가 시장을 뒷받침하고 있습니다. 줄기세포 기반 의약품은 임상 증상 완화뿐만 아니라 많은 만성질환의 근본 원인에 직접 작용하는 독특한 이점을 제공합니다. 예를 들어, VET CELL TECH는 자체 개발한 iPS 세포 기술을 활용한 강력한 파이프라인 구축으로 신뢰할 수 있는 품질과 원활한 유통을 동반한 대규모 줄기세포 치료제 생산을 실현하여 이러한 변화를 주도하고 있습니다. 고양이 만성 치은구내염, 고양이 만성신장질환, 개 아토피 피부염, 골관절염, 미래형 다발성 질환 등 주요 반려동물 건강문제에 대한 재생의료를 개발 중입니다. 이러한 치료법은 표준화되어 있고, 확장 가능하며, 실제 임상적 필요에 맞게 설계되어 노령 및 만성질환을 앓고 있는 반려동물을 돌보는 데 있어 중요한 공백을 메우고 있습니다. 이를 통해 더 많은 수의사들이 줄기세포 치료를 채택하고, 시장에서 첨단 재생의료에 대한 총 지출이 증가할 것으로 예상됩니다.

또한, 첨단 근거 중심의 재생의료를 수의학 주류에 도입하려는 노력이 시장 성장을 크게 견인하고 있습니다. 예를 들어, The Indian Express가 2025년 6월에 게재한 기사에 따르면, 갈란트의 고양이 중증 및 통증성 질환에 대한 줄기세포 치료제는 2026년 미국 FDA의 승인을 받을 것으로 예상됩니다. 이번 승인 획득은 큰 진전이며, 치료법의 안전성과 유효성을 입증함으로써 수의사와 반려동물 보호자의 신뢰를 높일 수 있을 것입니다. FDA 승인을 받은 줄기세포 제품이 출시되면 더 많은 병원이 채택할 가능성이 높아질 것이며, 투자자들도 이 분야에 더 많은 자금을 투자할 것으로 예상됩니다. 그 결과, 재생의료에 대한 전반적인 수용도가 높아져 산업의 발전을 촉진할 수 있을 것입니다.

또한, 반려동물 관련 지출의 증가는 이 산업을 크게 부추기고 있습니다. 현재 더 많은 주인이 반려동물을 가족처럼 여기고 건강 유지를 위해 고급 의료비를 기꺼이 지불할 의향이 있기 때문입니다. 예를 들어, APPA(미국 반려동물 제품 협회)에 따르면 미국의 반려동물 관련 지출은 2024년 1,519억 달러에서 2025년 1,570억 달러로 증가할 것으로 예상되며, 이는 반려동물 보호자들이 프리미엄 및 고급 수의학에 지속적으로 자금을 투자하고 있음을 보여줍니다. 이러한 경제적 부담의 증가는 줄기세포 치료와 같은 고부가가치 치료법의 도입을 직접적으로 뒷받침하고 있습니다. 이러한 치료법은 기존 치료법보다 비용이 많이 들 수 있지만, 골관절염, 골형성부전, 염증성 질환과 같은 만성질환에 탁월한 치료 효과를 제공합니다.

지역별 시장 대시보드
지역별 시장 점유율 분석, 2024년·2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 아랍에미리트
- 사우디아라비아
- 쿠웨이트
- 카타르
- 오만

제9장 경쟁 구도

시장 진입 기업 분류
- 시장 리더
- 신흥 기업
시장 점유율/평가 분석(2024년, 히트맵 분석)
기업 개요
- Boehringer Ingelheim International GmbH
- Vetherapy
- Vetstem, Inc.
- Ardent
- Cell Therapy Sciences
- Medrego
- StemcellX
- Magellan Stem Cells
- eQcell Inc
- Gallant

KSM

영문 목차

영문목차

Veterinary Stem Cell Therapy Market Summary

The global veterinary stem cell therapy market size was estimated at USD 154.07 million in 2024 and is projected to reach USD 311.03 million by 2033, growing at a CAGR of 8.62% from 2025 to 2033. The industry is witnessing significant growth driven by the increasing incidence of chronic and degenerative conditions in pets, continuous advancements in stem cell therapy technologies, rising pet humanization, and a greater willingness among owners to invest in advanced veterinary care.

The market is further supported by the growing demand for advanced, disease-modifying therapies in veterinary care. Stem cell-based drugs provide the unique advantage of relieving clinical symptoms as well as targeting the root cause of many chronic conditions. For instance, VET CELL TECH is helping drive this shift by building a strong pipeline using its own iPSC technology, which allows it to produce stem cell treatments on a large scale with reliable quality and smoother distribution. The company is developing regenerative therapies for major pet health problems like Feline Chronic Gingivostomatitis, chronic kidney disease in cats, atopic dermatitis in dogs, osteoarthritis, and several future conditions. Because these treatments are standardized, scalable, and designed for real clinical needs, they fill important gaps in care for older and chronically sick pets. This is expected to encourage more veterinarians to adopt stem cell therapies and increase overall spending on advanced regenerative care in the market.

In addition, initiatives undertaken to bring advanced, evidence-based regenerative therapies into mainstream veterinary care are significantly shaping market growth. For instance, according to an article published by The Indian Express, in June 2025, Gallant's stem cell therapy for a serious and painful condition in cats is expected to receive U.S. FDA approval in 2026. Getting this approval would be a big step forward, showing that the treatment is safe and truly works, which would boost confidence among veterinarians and pet owners. Once FDA-approved stem cell products become available, more clinics are likely to use them, investors may put more money into the field, and overall acceptance of regenerative treatments would grow, helping push the industry forward.

Furthermore, rising pet spending is giving a strong boost to the industry, because more pet owners now treat their animals like family and are willing to pay for advanced, high-quality medical care to keep them healthy. For instance, according to APPA, the rise in U.S. pet spending from USD 151.9 billion in 2024 to a projected USD 157 billion in 2025 shows that owners are consistently allocating more money toward premium and advanced veterinary care. This growing financial commitment directly supports the adoption of high-value treatments like stem cell therapy, which can be more expensive than traditional options but offer superior outcomes for chronic conditions such as osteoarthritis, dysplasia, and inflammatory diseases.

Global Veterinary Stem Cell Therapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary stem cell therapy market report based on product, application, animal type, end-use, and region.

Product Outlook (Revenue, USD Million, 2021 - 2033)
Autologous stem cell
Allogeneic stem cell
Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
Small Animals
Large Animals
Application Outlook (Revenue, USD Million, 2021 - 2033)
Orthopedics
Soft Tissue Repair
Other Applications
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Veterinary Hospitals/Clinics
Veterinary Academic & Research Institutes
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Animal Type
- 1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information/Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Model 1: Analysis
- 1.7.2. Model 2: Analysis
- 1.7.3. Model 3 Analysis
1.8. List of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary/Related Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increaisng Chronic Illness in Pets
  - 3.2.1.2. Technological Advancements in Stem Cell Therapy
  - 3.2.1.3. Supportive Initiatives By Government.
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High Treatment Cost
  - 3.2.2.2. Lack of Awareness
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
3.3. Technology Landscape
3.4. Pricing Analysis
3.5. Estimated Animal Population, By Key Species, Key Countries, 2021 - 2024
3.6. Product Pipeline Analysis
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Stem Cell Therapy Market: Product Estimates & Trend Analysis

4.1. Veterinary Stem Cell Therapy Market, By Product: Segment Dashboard
4.2. Veterinary Stem Cell Therapy Market, By Product Movement Analysis
4.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
4.4. Autologous Stem Cell
- 4.4.1. Autologous Stem Cell Market Estimates And Forecasts, 2021 - 2033(USD Million)
4.5. Allogeneic Stem Cell
- 4.5.1. Allogeneic Stem Cell Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 5. Veterinary Stem Cell Therapy Market: By Application Estimates & Trend Analysis

5.1. Veterinary Stem Cell Therapy Market, By Application: Segment Dashboard
5.2. Veterinary Stem Cell Therapy Market, By Application Movement Analysis
5.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by Application, 2021 to 2033 (USD Million)
- 5.3.1. Orthopedics
  - 5.3.1.1. Orthopedics Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.3.2. Soft Tissue Repair
  - 5.3.2.1. Soft Tissue Repair Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.3.3. Other Applications
  - 5.3.3.1. Other Applications Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 6. Veterinary Stem Cell Therapy Market: By Animal Type Estimates & Trend Analysis

6.1. Veterinary Stem Cell Therapy Market, By Animal Type: Segment Dashboard
6.2. Veterinary Stem Cell Therapy Market, By Animal Type Movement Analysis
6.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by Animal Type, 2021 to 2033 (USD Million)
6.4. Small Animals
- 6.4.1. Small Animals Market Estimates and Forecasts, 2021 - 2033(USD Million)
6.5. Large Animals
- 6.5.1. Large Animals Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 7. Veterinary Stem Cell Therapy Market: By End Use Estimates & Trend Analysis

7.1. Veterinary Stem Cell Therapy Market, By End Use: Segment Dashboard
7.2. Veterinary Stem Cell Therapy Market, By End Use Movement Analysis
7.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by End Use, 2021 to 2033 (USD Million)
7.4. Veterinary Hospitals/Clinics
- 7.4.1. Veterinary Hospitals/Clinics Market Estimates and Forecasts, 2021 - 2033(USD Million)
7.5. Veterinary Academic & Research Institutes
- 7.5.1. Veterinary Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 8. Veterinary Stem Cell Therapy Market: By Regional Estimates & Trend Analysis

8.1. Region Market Dashboard
8.2. Region Market Share Analysis, 2024 & 2033
8.3. North America
- 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. U.S
  - 8.3.2.1. Key Country Dynamics
  - 8.3.2.2. Competitive Scenario
  - 8.3.2.3. Regulatory Framework
  - 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. Canada
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Competitive Scenario
  - 8.3.3.3. Regulatory Framework
  - 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.4. Mexico
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Competitive Scenario
  - 8.3.4.3. Regulatory Framework
  - 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4. Europe
- 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. UK
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Competitive Scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Germany
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Competitive Scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. France
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.5. Italy
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Competitive Scenario
  - 8.4.5.3. Regulatory Framework
  - 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.6. Spain
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Competitive Scenario
  - 8.4.6.3. Regulatory Framework
  - 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.7. Denmark
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Competitive Scenario
  - 8.4.7.3. Regulatory Framework
  - 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.8. Sweden
  - 8.4.8.1. Key Country Dynamics
  - 8.4.8.2. Competitive Scenario
  - 8.4.8.3. Regulatory Framework
  - 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.9. Norway
  - 8.4.9.1. Key Country Dynamics
  - 8.4.9.2. Competitive Scenario
  - 8.4.9.3. Regulatory Framework
  - 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Asia Pacific
- 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Japan
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Competitive Scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. China
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. India
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Competitive Scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Australia
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Competitive Scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Thailand
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. South Korea
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Competitive Scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Latin America
- 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Brazil
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Competitive Scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. Argentina
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Competitive Scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. MEA
- 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. South Africa
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Competitive Scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. UAE
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Competitive Scenario
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.4. Saudi Arabia
  - 8.7.4.1. Key Country Dynamics
  - 8.7.4.2. Competitive Scenario
  - 8.7.4.3. Regulatory Framework
  - 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.5. Kuwait
  - 8.7.5.1. Key Country Dynamics
  - 8.7.5.2. Competitive Scenario
  - 8.7.5.3. Regulatory Framework
  - 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.6. Qatar
  - 8.7.6.1. Key Country Dynamics
  - 8.7.6.2. Competitive Scenario
  - 8.7.6.3. Regulatory Framework
  - 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.7. Oman
  - 8.7.7.1. Key Country Dynamics
  - 8.7.7.2. Competitive Scenario
  - 8.7.7.3. Regulatory Framework
  - 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Market Participant Categorization
- 9.1.1. Market Leaders
- 9.1.2. Emerging Players
9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
9.3. Company Profiles
- 9.3.1. Boehringer Ingelheim International GmbH
  - 9.3.1.1. Participant's Overview
  - 9.3.1.2. Financial Performance
  - 9.3.1.3. Product Benchmarking
  - 9.3.1.4. Strategic Initiatives
- 9.3.2. Vetherapy
  - 9.3.2.1. Participant's Overview
  - 9.3.2.2. Financial Performance
  - 9.3.2.3. Product Benchmarking
  - 9.3.2.4. Strategic Initiatives
- 9.3.3. Vetstem, Inc.
  - 9.3.3.1. Participant's Overview
  - 9.3.3.2. Financial Performance
  - 9.3.3.3. Product Benchmarking
  - 9.3.3.4. Strategic Initiatives
- 9.3.4. Ardent
  - 9.3.4.1. Participant's Overview
  - 9.3.4.2. Financial Performance
  - 9.3.4.3. Product Benchmarking
  - 9.3.4.4. Strategic Initiatives
- 9.3.5. Cell Therapy Sciences
  - 9.3.5.1. Participant's Overview
  - 9.3.5.2. Financial Performance
  - 9.3.5.3. Product Benchmarking
  - 9.3.5.4. Strategic Initiatives
- 9.3.6. Medrego
  - 9.3.6.1. Participant's Overview
  - 9.3.6.2. Financial Performance
  - 9.3.6.3. Product Benchmarking
  - 9.3.6.4. Strategic Initiatives
- 9.3.7. StemcellX
  - 9.3.7.1. Participant's Overview
  - 9.3.7.2. Financial Performance
  - 9.3.7.3. Product Benchmarking
  - 9.3.7.4. Strategic Initiatives
- 9.3.8. Magellan Stem Cells
  - 9.3.8.1. Participant's Overview
  - 9.3.8.2. Financial Performance
  - 9.3.8.3. Product Benchmarking
  - 9.3.8.4. Strategic Initiatives
- 9.3.9. eQcell Inc
  - 9.3.9.1. Participant's Overview
  - 9.3.9.2. Financial Performance
  - 9.3.9.3. Product Benchmarking
  - 9.3.9.4. Strategic Initiatives
- 9.3.10. Gallant
  - 9.3.10.1. Participant's Overview
  - 9.3.10.2. Financial Performance
  - 9.3.10.3. Product Benchmarking
  - 9.3.10.4. Strategic Initiatives

한글목차

수의용 줄기세포 치료 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수 동향과 범위

제4장 수의용 줄기세포 치료 시장 : 제품별 추정·동향 분석

제5장 수의용 줄기세포 치료 시장 : 용도별 추정·동향 분석

제6장 수의용 줄기세포 치료 시장 : 동물 유형별 추정·동향 분석

제7장 수의용 줄기세포 치료 시장 : 최종 용도별 추정·동향 분석

제8장 수의용 줄기세포 치료 시장 : 지역별 추정·동향 분석